THE AIM OF STUDY was the evaluation of occurrence frequency of increased concentration of p53 protein in serum of patients with COPD or NSCLC.
Material and methods: Participants have been enrolled to the one of three studied groups: patients with COPD, patients with NSCLC and healthy subjects. In each patient serum concentration of p53 protein was measured with ELISA method (photometric immunoassay ELISA, ROCHE Molecular Biochemicals, Manheim, Germany). Comparative analysis of frequency of p53 occurrence in serum in three studied group has been done with respect to nicotine addiction in COPD and NSCLC groups. Chi-squared test was used for statistical analysis. 95% confidence interval was set for statistically significant differences.
Results: 164 participants was enrolled to the study including: 53 with NSCLC, 59 with COPD and 52 healthy control. Presence of p53 protein in serum was observed in 45% of patients with NSCLC, 34% of patients with COPD, and in 11.5% healthy people. In healthy subjects increased serum concentration of p53 was found out significantly more seldom than in COPD (p = 0.006) and NSCLC (p = 0.0001) groups. There was no significant difference between prevalence of p53 protein in serum of patients with NSCLC or COPD (p = 0.2).
Conclusions: P53 protein is observed in serum three times more often in patients with COPD than healthy subjects. Preasumably, chronic inflammation in bronchial tree in course of COPD could be predisposing factor for p53 mutation and synthesis of pathological p53 protein.